Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) is characterized by chronic active B cell receptor (BCR) signaling.
• This signaling pathway is crucial for the proliferation and survival of ABC DLBCL cells.

Purpose of the Study:

• To elucidate the role of the CARD11-MALT1-BCL10 (CBM) complex in BCR-dependent NF-κB activation in ABC DLBCL.
• To investigate the therapeutic potential of targeting E3 ubiquitin ligases within the CBM complex.

Main Methods:

• Biochemical assays to analyze CBM complex composition and ubiquitination.
• Cell-based assays to assess NF-κB pathway activation and cell viability.
• Treatment of ABC DLBCL cell lines with SMAC mimetics.

Main Results:

• The CBM complex incorporates E3 ubiquitin ligases cIAP1 and cIAP2, which are essential for BCR-induced NF-κB activation.
• cIAP1/2 mediate K63-linked polyubiquitination of the CBM complex components, facilitating IKK recruitment and activation.
• SMAC mimetics, by targeting cIAP1/2 for degradation, effectively suppress NF-κB signaling and selectively kill BCR-dependent ABC DLBCL cells.

Conclusions:

• cIAP1 and cIAP2 are critical components of the BCR signaling pathway in ABC DLBCL.
• Targeting cIAP1/2 with SMAC mimetics represents a promising therapeutic strategy for ABC DLBCL.
• Further clinical evaluation of SMAC mimetics in patients with ABC DLBCL is warranted.